Yarrow Bioscience (YARW) Receivables - Other (2020 - 2021)
Yarrow Bioscience's (YARW) quarterly Receivables - Other came in at $5.5 million in Q4 2021, down 5.17% YoY from $5.8 million in Q4 2020, and down 24.66% on a QoQ basis from $7.3 million in Q3 2021.
Yarrow Bioscience (YARW) Receivables - Other (2020 - 2021) Analysis & Trends
Yarrow Bioscience (YARW) has 2 years of Receivables - Other data on file, last reported at $5.5 million in Q4 2021.
- Quarterly Receivables - Other fell 5.17% year-over-year to $5.5 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $5.5 million (down 5.17% YoY) and the FY2021 annual result came in at $5.5 million, down 5.17% from the prior year.
- Receivables - Other eased to $5.5 million in Q4 2021, from $7.3 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $8.1 million in Q1 2021 to a low of $4.0 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 5.50 Mn |
| Dec 31, 2021 | 5.50 Mn |
| Sep 30, 2021 | 7.30 Mn |
| Sep 30, 2021 | 7.30 Mn |
| Jun 30, 2021 | 7.60 Mn |
| Jun 30, 2021 | 7.60 Mn |
| Mar 31, 2021 | 8.10 Mn |
| Mar 31, 2021 | 8.10 Mn |
| Dec 31, 2020 | 5.80 Mn |
| Dec 31, 2020 | 5.80 Mn |
| Sep 30, 2020 | 5.60 Mn |
| Sep 30, 2020 | 5.60 Mn |
| Jun 30, 2020 | 4.00 Mn |
| Jun 30, 2020 | 4.00 Mn |